New immune therapy aims to tackle tough childhood leukemia

NCT ID NCT02443831

Recruiting now Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new type of immunotherapy for children and young adults with a high-risk or relapsed form of acute lymphoblastic leukemia. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells that carry two specific markers (CD19 and CD22). The study will enroll about 50 participants and will primarily look at safety and whether the treatment can clear the leukemia from the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD19+CD22 CAR T-cells (a type of immune cell therapy)
What this could lead to: If it works, this could offer a new treatment option for children with hard-to-treat leukemia that has come back or not responded to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 50 participants, so it is not yet proven to be safe or effective. There are also risks of serious side effects from the chemotherapy and cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Great Ormond Street Hospital
RECRUITING

London, United Kingdom
Manchester Royal Children's Hospital
RECRUITING

Manchester, United Kingdom
University College Hospital
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.